iah0968
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Aug 31, 2021 (NCT04934514)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06504732 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2024 | SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT05673512 | Phase 2/Phase 3 (Phase 3) | May 12, 2023 | SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT05991518 | Phase 1/Phase 2 (Phase 2) | Apr 25, 2023 | Fudan University, SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT04934514 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2021 | China Medical University, SUNHO（China）BioPharmaceutical CO., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SUNHO（China）BioPharmaceutical CO., Ltd. | For profit | 4 | 4 | 2 | 2021 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1